Taysha Gene Therapies Inc (TSHA)
2.96
+0.07
(+2.42%)
USD |
NASDAQ |
May 22, 16:00
2.95
-0.01
(-0.34%)
After-Hours: 20:00
Taysha Gene Therapies Research and Development Expense (Quarterly): 20.66M for March 31, 2024
Research and Development Expense (Quarterly) Chart
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| March 31, 2024 | 20.66M |
| December 31, 2023 | 12.68M |
| September 30, 2023 | 11.79M |
| June 30, 2023 | 19.79M |
| March 31, 2023 | 12.51M |
| December 31, 2022 | 12.71M |
| September 30, 2022 | 16.77M |
| June 30, 2022 | 23.51M |
| March 31, 2022 | 38.18M |
| Date | Value |
|---|---|
| December 31, 2021 | 37.92M |
| September 30, 2021 | 39.53M |
| June 30, 2021 | 30.64M |
| March 31, 2021 | 23.85M |
| December 31, 2020 | 12.26M |
| September 30, 2020 | 11.06M |
| June 30, 2020 | 3.062M |
| March 31, 2020 | 5.514M |
| December 31, 2019 | 0.987M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
0.987M
Minimum
Dec 2019
39.53M
Maximum
Sep 2021
18.52M
Average
14.74M
Median
Research and Development Expense (Quarterly) Benchmarks
| Aquestive Therapeutics Inc | 5.932M |
| Lifecore Biomedical Inc | 2.116M |
| Relmada Therapeutics Inc | 13.31M |
| ACADIA Pharmaceuticals Inc | 59.68M |
| Cyclacel Pharmaceuticals Inc | 2.802M |